Dossier
Ervebo
Coverage of Ervebo in the Nexus archive.
- STAT+: Global coalition to fast-track three vaccines targeting Ebola outbreak with $62 million in funding
A global coalition is fast-tracking three vaccines targeting the Bundibugyo ebolavirus, with $62 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The current outbreak in the Democratic Republic of Congo lacks a licensed vaccine, as Merck’s Ervebo only targets the Zaire ebolavirus.
- With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
The Ebola outbreak in the Democratic Republic of the Congo is spreading rapidly and is already the fourth largest on record. There is no approved vaccine for the Bundibugyo species of the virus, but the existing licensed Ebola vaccine, Merck's Ervebo, may offer some protection. The outbreak is occurring in a conflict zone, making containment a challenge.